

## FACSIMILE COVER SHEET

**SALIWANCHIK, LLOYD & SALIWANCHIK**

A Professional Association  
2421 N.W. 41<sup>st</sup> Street  
Suite A-1  
Gainesville, FL 32606

Telephone (352) 375-8100  
Facsimile (352) 372-5800

**FAX RECEIVED**

JAN 22 2003

**GROUP 1600**

---

**TO:** Group Art Unit 1645  
**FROM:** Frank C. Eisenschenk, Ph.D.  
**COMPANY:** U.S. Patent & Trademark Office  
**DATE:** January 21, 2003  
**FAX NO.:** 1-703-308-4242  
**NO. OF PAGES:** 6  
**(INCLUDING COVER SHEET)**

---

**SUBJECT/MESSAGE:** U.S. Patent Application Docket No. G-078US04CIP  
Full-length Human cDNAs Encoding Potentially Secreted Proteins  
(Dumas Milne Edwards, et al.)  
Serial No. 09/876,997; Filed June 8, 2001

Attached: Supplemental Information Disclosure Statement  
Under 37 C.F.R. §§ 1.97 and 1.98  
Form PTO/SB/08A B (3 pages)

**THIS IS AN OFFICIAL DOCUMENT.**  
**PLEASE DELIVER IMMEDIATELY.**


---

*The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.*

---

*If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.*

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on January 21, 2003.

  
Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

Examining Group 1645

Patent Application

Docket No. G-078US04CIP

Serial No. 09/876,997

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : unknown  
Art Unit : 1645  
Applicant(s) : Jean-Baptiste Dumas Milne Edwards *et al.*  
Serial No. : 09/876,997  
Filed : June 8, 2001  
Confirm. No. : 2239  
For : Full-length Human cDNAs Encoding Potentially Secreted Proteins

Assistant Commissioner for Patents  
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, Applicants would like to bring to the attention of the Examiner, the references cited in the following patent application:

U.S. Serial No. 09/731,872, filed December 7, 2000, pending.

37 C.F.R. § 1.98(d) states that a copy of any patent, publication, or other information listed in an information disclosure statement is not required to be provided if it was previously cited by or submitted to the Office in a prior application, provided that the prior application is properly identified in the statement and relied on for an earlier filing date under 35 U.S.C. § 120.

2

Docket No. G-078US04CIP  
Serial No. 09/876,997

As copies of the references cited on the attached form PTO/SB/08, can be found in patent application Serial Number 09/731,872, filed December 7, 2000, copies of those references are not provided herewith. The subject application, Serial No. 09/876,997, claims the benefit under 35 U.S.C. § 120 of the filing date of patent application Serial Number 09/731,872. Accordingly, Applicants respectfully request that the copies of references supplied in the Information Disclosure Statement of the 09/731,872 application, as well as references cited during prosecution thereof, be made of record in this application.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98 are met by the foregoing statements.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik  
A Professional Association  
2421 N.W. 41<sup>st</sup> Street, Suite A-1  
Gainesville, FL 32606-6669

FCE/jaj

Attachment: Form PTO/SB/08A & B (3 pages)

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	09/876,997		
		Filing Date	June 8, 2001		
		First Named Inventor	J.-B. Dumas Milne Edwards		
		Art Unit	1645		
		Examiner Name	unknown		
Sheet	1	of	3	Attorney Docket Number	G-078US04CIP

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	F1	EP	1130094 A2 (CD-ROM)	07/07/2000 *	Helix Research Institute	
	F2	WO	98/55814 A2	12/10/1998	Genetics Institute, Inc.	
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

3

**Complete if Known**

Application Number	09/876,997
Filing Date	June 8, 2001
First Named Inventor	J.-B. Dumas Milne Edwards
Group Art Unit	1645
Examiner Name	unknown
Attorney Docket Number	G-078US04CIP

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	BOUGUELERET, L. <i>et al.</i> , "Extended cDNAs useful for expressing secreted proteins and to obtain specific antibodies", 2000, pp. 203-204, Accession No. AAY59685.	
	R2	CAMERON, C. <i>et al.</i> , "Function and Protective Capacity of <i>Treponema pallidum</i> subsp. <i>pallidum</i> Glycerophosphodiester Phosphodiesterase", <i>Infection and Immunity</i> (1998), pp. 5763-5770, Vol. 66, No. 12, American Society for Microbiology.	
	R3	DOWNES, G. <i>et al.</i> , "Structure and Mapping of the G Protein $\gamma 3$ Subunit Gene and a Divergently Transcribed Novel Gene, <i>Gng31g</i> ", <i>Genomics</i> (1998), pp. 220-230, Vol. 53, Academic Press.	
	R4	INOUE, S. <i>et al.</i> , "Growth Suppression of <i>Escherichia coli</i> by Induction of Expression of Mammalian Genes with Transmembrane or ATPase Domains", <i>Biochem. Biophys. Res. Comm.</i> (2000), pp. 553-561, Vol. 268, Academic Press.	
	R5	JANSON, H., <i>et al.</i> , "Protein D, the Glycerophosphodiester Phosphodiesterase from <i>Haemophilus influenzae</i> with Affinity for Human Immunoglobulin D, Influences Virulence in a Rat Otitis Model", <i>Infection and Immunity</i> , 1994, pp. 4848-4854, Vol. 62, No. 11, American Society for Microbiology.	
	R6	LARSON, T., <i>et al.</i> , "Periplasmic Glycerophosphodiester Phosphodiesterase of <i>Escherichia coli</i> , a New Enzyme of the <i>gip</i> Regulon", <i>J. Biol. Chem.</i> , 1983, pp. 5428-5432, Vol. 258, No. 9.	
	R7	MAGRÉ, J. <i>et al.</i> , "Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13", <i>Nature Genetics</i> (2001), pp. 365-370, Vol. 28.	
	R8	MELDRUM, Brian, "Glutamate as a Neurotransmitter in the Brain: Review of Physiology and Pathology", <i>The Journal of Nutrition - Supplement</i> (presented at the International Symposium on Glutamate, 1998), 2000, pp. 1007S-1015S, Pub: American Society for Nutritional Sciences.	
	R9	MUNSON, R. <i>et al.</i> , "Protein D, a Putative Immunoglobulin D-Binding Protein Produced by <i>Haemophilus influenzae</i> , is Glycerophosphodiester Phosphodiesterase", <i>J. Bacteriology</i> , 1993, pp. 4569-4571, Vol. 175, No. 14.	
	R10	NEER, Eva, "Heterotrimeric G Proteins: Organizers of Transmembrane Signals", <i>Cell</i> , 1995, pp. 249-257, Vol. 80, Cell Press.	
	R11	SCHOEPP, D. <i>et al.</i> , "Metabotropic glutamate receptors in brain function and pathology", <i>TIPS</i> , 1993, pp. 13-20, Vol. 14, Elsevier Science Publishers, Ltd., UK.	
	R12	ZHENG, B. <i>et al.</i> , "MIR16, a putative membrane glycerophosphodiester phosphodiesterase, interacts with RGS16, <i>PNAS</i> , 2000, pp. 3999-4004, Vol. 97, No. 8.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 3

**Complete if Known**

Application Number	09/876,997
Filing Date	June 8, 2001
First Named Inventor	J.-B. Dumas Milne Edwards
Group Art Unit	1645
Examiner Name	unknown
Attorney Docket Number	G-078US04CIP

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R13	ZHENG, B. et al., "MIR16, a putative membrane glycerophosphodiester phosphodiesterase, interacts with RGS16, <i>Proc. Natl. Acad. Sci. U.S.A.</i> (2000), pp. 3999-4004, Vol. 97, No. 8, Accession No. AAF65234 (bases 1 to 331).	
	R14	ZHENG, B. et al., "MIR16, a putative membrane glycerophosphodiester phosphodiesterase, interacts with RGS16, <i>Proc. Natl. Acad. Sci. U.S.A.</i> (2000), pp. 3999-4004, Vol. 97, No. 8, Accession No. AF212862 (bases 1 to 1200).	
	R15	Glycerophosphoryl Diester Phosphodiesterase <i>Escherichia coli</i> (1989), NiceProt View of SWISS-PROT: P10908.	
	R16	Glycerophosphoryl Diester Phosphodiesterase, periplasmic [Precursor] <i>Escherichia coli</i> (1991), NiceProt View of SWISS-PROT: P09394.	
	R17	Glycerophosphoryl Diester Phosphodiesterase [Precursor] <i>Haemophilus influenzae</i> (1995), NiceProt View of SWISS-PROT: Q06282.	
	R18	Similar to G Protein Gamma 3 Linked Gene <i>Homo Sapiens</i> (2001), NiceProt View of SWISS-PROT: Q9BSQ0.	
	R19	Hypothetical 43.1 kDa protein <i>Mus musculus</i> (2000), NiceProt View of SWISS-PROT: Q9JMF1.	
	R20		
	R21		
	R22		
	R23		
	R24		
	R25		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.